As the National Medical Products Administration has consecutively approved multiple new stem-cell drugs to enter clinical trial phases, China's stem-cell therapy industry is rapidly advancing into an era of "clinical validation." Yet, behind this growing enthusiasm, a pressing reality is becoming increasingly evident: many cutting-edge research teams, despite their technological advancements, are facing significant hurdles in the stem-cell IND (Investigational New Drug) application process—struggling with incomplete submissions, encountering rigorous scrutiny, undergoing repeated revisions, and even missing critical R&D timelines altogether.

A leader from a biotech company candidly shared: "We spent five years completing our stem-cell mechanism research and in vitro validation, yet we’ve been stuck for nearly two years trying to advance our stem-cell IND application—not because our technology isn’t robust, but because we couldn’t communicate it in a way regulators could understand." This isn’t an isolated case. According to incomplete statistics, over 60% of domestic stem-cell IND applications submitted in the past three years have faced requests for additional information (commonly referred to as "supplementing data"), with some projects even being forced to halt altogether after failing to effectively address the reviewers’ feedback. As a result, the industry has increasingly come to accept that "technological leadership does not automatically translate into clinical advancement."

1. Why is a stem cell IND so challenging?

Stem cell therapy product development is rapidly accelerating, but many innovators still face significant challenges as they prepare for the "critical leap" toward clinical trials—specifically, during the stem cell IND submission process. Unlike traditional chemical drugs or large-molecule biologics, stem cell therapies are living-cell-based, involve complex manufacturing processes, and exhibit inherent batch-to-batch variability. These unique characteristics place heightened regulatory and review demands on ensuring their safety and maintaining consistent quality.

In recent years, the Center for Drug Evaluation (CDE) under the National Medical Products Administration has successively released documents such as the "Guidelines for Ethical Review of Clinical Research on Stem Cell-Related Products" and the "Technical Guidance Principles for Clinical Trials of Human-Derived Stem Cells and Their Differentiated Cell-Based Therapeutic Products," providing industry with clear directional guidance. However, during the actual application process, companies have widely reported that there remain significant ambiguities regarding the level of detail in technical standards and their practical implementation. In particular, challenges persist in areas such as process change management, definition of quality attributes, and bridging non-clinical studies, where a unified operational consensus is still lacking.

Several professionals involved in supporting stem cell IND reviews pointed out that the current challenges in submitting stem cell-related projects primarily revolve around five key areas: First, while R&D teams possess core technologies, they often struggle to translate experimental data into standardized documentation that adheres to the CTD format and aligns with regulatory review logic. Second, frequent process optimizations are common, yet there’s a lack of proactive assessment regarding what constitutes "major changes," which can easily raise concerns among regulators about the consistency of product quality. Third, insufficient identification of Critical Quality Attributes (CQAs) leads to fragmented quality-control strategies, making it difficult to establish a robust, closed-loop evidence chain. Fourth, during Pre-IND meetings, poorly organized submissions and inadequate preparation for responses often result in missed opportunities to build early consensus with regulatory agencies. Finally, the overall submission strategy lacks systematic planning, leading to a cycle of repeated resubmissions and reactive responses—severely delaying the pace of research and development.

"Behind this lies a deeper issue: the disconnect between R&D and regulatory functions," said a registration consultant who has long worked on cell therapy projects. "Many teams don’t kick off registration preparations until late in the R&D phase, treating the stem cell IND submission as a last-minute sprint—when in fact, it should be a systematic, end-to-end process integrated throughout the entire development journey." This perspective is backed by several successful case studies. Industry observers have noted that projects which efficiently navigate the stem cell IND filing process typically bring in teams with robust regulatory expertise early on, enabling them to proactively establish quality systems, clearly define process boundaries, and craft a coherent regulatory narrative—thereby significantly mitigating compliance risks down the line. As regulatory frameworks continue to evolve and mature, the industry is increasingly recognizing the importance of "registration science." Going forward, a company’s true competitive edge in the stem cell space may hinge not only on its ability to innovate technologically but also on its capacity to simultaneously build and align robust registration capabilities with those innovations.

2. The Game-Changer: Who’s Paving the "Path to Certainty"?

As stem cell therapy moves toward industrialization, a new service model—increasingly focused on being "registration-driven"—is gradually emerging: the Stem Cell CQDMO (Contract Quality & Development and Manufacturing Organization). Compared to the traditional stem cell CDMO model, which centers primarily on manufacturing, the Stem Cell CQDMO goes beyond quality systems, process development, and clinical-grade production—it also extends into registration strategy design and support for IND submissions related to stem cells. Importantly, this approach emphasizes a deep understanding of regulatory frameworks and the systematic development of clear, well-structured pathways for regulatory approval.

The rise of this model stems from the widespread industry challenges: despite possessing cutting-edge technology, many R&D institutions still struggle to efficiently complete stem cell IND applications when confronted with complex regulatory requirements, often leading to project delays—or even outright stagnation. Against this backdrop, service platforms that offer end-to-end support, from early-stage R&D involvement and process optimization assistance to seamless coordination throughout the entire registration and submission process, are increasingly attracting the attention of innovative companies.

Among them, Jiuzhitang Maker is one of the earlier companies to have successfully implemented the stem cell CQDMO model. Publicly available data shows that the company has already supported three innovative stem cell drug projects in securing implicit clinical approval from China’s National Medical Products Administration (NMPA), enabling their transition into subsequent clinical phases. The first project—identified by application number JXSL1900126—is currently in Phase IIa clinical trials, jointly conducted by Beijing Tiantan Hospital, Peking University Third Hospital, and Beijing Tongren Hospital. The second project—application number CXSL2300202—is being advanced in collaboration with the First Affiliated Hospital of Guangzhou Medical University, also progressing smoothly into Phase IIa. Meanwhile, the third project—application number CXSL2400859—has partnered with Beijing Anding Hospital to initiate its Phase I clinical trial. These projects are specifically targeting highly complex therapeutic areas such as the nervous system and respiratory system, placing heightened demands on the stability, quality control, and clinical trial design of cellular products. Notably, the overall timeline—from project initiation to approval—has remained remarkably efficient, underscoring the platform’s exceptional capability to swiftly navigate the challenging process of IND submissions for stem cell therapies aimed at high-complexity indications, while leveraging seamless cross-functional collaboration throughout the entire development pipeline.

More notably, Jiuzhitang Maker is currently the only domestic company that has successfully completed IND applications for both imported and domestically sourced mesenchymal stem cells. This hands-on experience—spanning diverse cellular origins, donor backgrounds, and manufacturing processes across borders—demonstrates not only the broad adaptability of its technological approach but also gives the company a distinct systemic advantage when developing registration strategies. Whether navigating differences in cellular resources between domestic and international markets or aligning with varying quality-control requirements across distinct production platforms, Jiuzhitang Maker leverages its real-world application expertise to deliver forward-thinking, highly actionable solutions tailored specifically for innovative pharmaceutical companies.

In an environment where the standards for current stem cell IND applications are becoming increasingly clear, yet implementation details remain challenging, platforms offering end-to-end service capabilities are emerging as the critical link between scientific breakthroughs and clinical translation. For small to medium-sized innovative companies, particularly those without dedicated regulatory teams, partnering with a collaborator that combines both technical expertise and strong compliance capabilities has become a key strategy for accelerating their R&D progress.

3. The Real Barrier: It’s Not the Equipment—but "Registration Mindset."

During surveys of multiple applicant entities, one trend has gradually become clear: the projects that successfully completed stem cell IND submissions were often not the teams that first initiated research and development, but rather the organizations that first began mapping out their regulatory pathways.

Take Jiuzhitang Maker as an example—several stem-cell projects it has supported exhibit a distinct "front-loaded" service approach. Publicly available information reveals that the platform typically gets involved early in the R&D phase, helping companies refine product characteristics, identify potential process risks, and deliver a quantifiable "Stem Cell IND Submission Roadmap." This roadmap clearly outlines critical milestones and sets the pace for data preparation. By adopting this model, Jiuzhitang Maker challenges the conventional linear mindset of "initiating the submission process only after R&D is complete," instead integrating regulatory strategies seamlessly into the entire development cycle. Notably, in crucial areas such as process change management and defining Critical Quality Attributes (CQA), the platform team proactively assists clients in avoiding late-stage review concerns caused by incomplete or disconnected data.

Notably, the team members come from diverse backgrounds spanning both pharmaceutical registration and clinical medicine, with an average of over ten years of industry experience. They have been deeply involved for many years in supporting the registration review and evaluation of chemical drugs, biologics, and cell therapy products. This expertise enables them to go beyond mere technical descriptions when preparing CTD documentation, helping to build evidence chains that align with CDE’s review logic—shifting the focus from "clearly explaining scientific principles" to "demonstrating that the product is controllable and approvable." Additionally, the platform offers comprehensive, end-to-end support throughout key stages, including preparation for Pre-IND meetings, responding to CDE correspondence, and organizing supplementary submission materials. Several partners have reported that this seamless, collaborative approach has significantly enhanced communication efficiency with regulatory authorities, ultimately shortening the overall approval timeline.

Industry analysts believe that these services have moved beyond the traditional concept of "outsourcing," increasingly resembling a strategic partnership role. Particularly in highly complex fields like stem cells, where technology alone serves as the entry ticket, the ability to efficiently navigate and successfully complete a stem cell IND application is now becoming the critical factor determining the ultimate success—or failure—of translating innovative research into practical applications.

4. A Trillion-Dollar Blue Ocean Requires More "Pathfinders"

According to the publicly released "In-depth Research and Strategic Development Consulting Report on the Global and China Stem Cell Industry (2025-2030)," the global stem cell market is projected to surpass US$100 billion by 2030, while China's market is expected to exceed 200 billion RMB. Amid this growth trend, China is steadily transitioning from a technology follower to an active player in independent innovation. At the policy level, the country continues to ramp up its support for innovative drug and medical device R&D. Meanwhile, the National Medical Products Administration is advancing reforms in its review and approval processes, and several provinces and cities have introduced specialized support policies—offering assistance in areas such as R&D funding, clinical trial registration, and industrial translation—to accelerate the journey of stem cell technologies from the lab to clinical applications.

How to ensure that outstanding scientific research no longer gets stuck in the bureaucratic maze of regulatory submissions—and instead truly reaches patients—has become a critical issue for industry development. Industry experts believe that, in the coming years, stem cell CQDMO platforms capable of handling Investigational New Drug (IND) applications will emerge as scarce resources. These platforms aren’t just "outsourcing service providers"; they serve as vital "translators" and "navigators," bridging the gap between scientific innovation and regulatory requirements. Compared to traditional stem cell CDMOs that merely offer manufacturing services, or registration outsourcing firms focused solely on documentation, the real value lies with organizations that are deeply involved throughout the entire IND submission process. Jiuzhitang Maker stands out precisely because its technical team not only boasts extensive experience in drug registration but also possesses a thorough understanding of stem cell production processes, key quality attributes, and their clinical application scenarios. This unique interdisciplinary expertise enables the team to engage in high-quality, science-based, risk-oriented discussions with regulatory authorities during the submission phase—effectively shifting the dynamic from "passive response" to "proactive guidance."

"In the stem cell field, speed is life, and certainty is what gives you a competitive edge," noted an investor. "After all, whoever can help innovators avoid unnecessary detours holds the key to unlocking the future."

As more and more research teams realize that "a stem cell IND application isn’t the end—it’s just the beginning"—China’s stem cell drug development may be reaching a pivotal moment, shifting from "technological catch-up" to "systemic breakthrough." And on this journey toward clinical translation, the value of specialized expertise has never been clearer.